Implementation of HPV-based Cervical Cancer Screening
Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network Across Rural Greece: The GRECOSELF Study
02 Νοε 20
12:08 ΜΜ
Cancer Prev Res (Phila). 2019 Oct;12(10):701-710.doi: 10.1158/1940-6207.CAPR-19-0192. Epub 2019 Aug 19.

Theodoros Agorastos, Kimon Chatzistamatiou, Athena Tsertanidou, Evangelia Mouchtaropoulou, Konstantinos Pasentsis, Anastasia Kitsou, Theodoros Moysiadis, Viktoria Moschaki, Alkmini Skenderi, Evangelia Katsiki, Stamatia Aggelidou, Ioannis Venizelos, Maria Ntoula , Alexandros Daponte , Polyxeni Vanakara, Antonios Garas, Theodoros Stefos , Thomas Vrekoussis, Vasilis Lymberis, Emmanuel N Kontomanolis , Antonis Makrigiannakis , George Manidakis, Efthimios Deligeoroglou , Theodoros Panoskaltsis , George O Decavalas , George Michail , Ioannis Kalogiannidis , George Koukoulis , Paraskevi Zempili , Despina Halatsi, Theoni Truva, Vaia Piha, Georgia Agelena , Athanasia Chronopoulou , Violetta Vaitsi , Ekaterini Chatzaki, Minas Paschopoulos, George Adonakis, Andreas M Kaufmann, Anastasia Hadzidimitriou , Kostas Stamatopoulos

Free Article.


Self-sampling for human papillomavirus (HPV) testing is an alternative to physician sampling particularly for cervical cancer screening nonattenders. The GRECOSELF study is a nationwide observational cross-sectional study aiming to suggest a way to implement HPV-DNA testing in conjunction with self-sampling for cervical cancer screening in Greece, utilizing a midwifery network. Women residing in remote areas of Greece were approached by midwives, of a nationwide network, and were provided with a self-collection kit (dry swab) for cervicovaginal sampling and asked to answer a questionnaire about their cervical cancer screening history. Each sample was tested for high-risk (hr) HPV with the Cobas HPV test. HrHPV-Positive women were referred to undergo colposcopy and, if needed, treatment according to colposcopy/biopsy results. Between May 2016 and November 2018, 13,111 women were recruited. Of these, 12,787 women gave valid answers in the study questionnaire and had valid HPV-DNA results; hrHPV prevalence was 8.3%; high-grade cervical/vaginal disease or cancer prevalence was 0.6%. HrHPV positivity rate decreased with age from 20.7% for women aged 25-29 years to 5.1% for women aged 50-60 years. Positive predictive value for hrHPV testing and for HPV16/18 genotyping ranged from 5.0% to 11.6% and from 11.8% to 27.0%, respectively, in different age groups. Compliance to colposcopy referral rate ranged from 68.6% (for women 25-29) to 76.3% (for women 40-49). For women residing in remote areas of Greece, the detection of hrHPV DNA with the Cobas HPV test, on self-collected cervicovaginal samples using dry cotton swabs, which are provided by visiting midwives, is a promising method for cervical cancer secondary prevention.

Created by